Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health
Notice Number:
NOT-OD-24-146

Key Dates

Release Date:

June 24, 2024

First Available Due Date:
July 15, 2024
Expiration Date:
July 14, 2027

Related Announcements

  • Jan 20, 2024 - Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required). See PAR-24-084
  • Jan 18, 2024 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional). See PAR-24-122 
  • Dec 21, 2023 - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required). See PAR-24-086
  • Dec 21, 2023 - Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required). See PAR-24-090
  • Dec 21, 2023 - Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required). See PAR-24-087
  • Dec 21, 2023 - NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required). See PAR-24-083
  • Dec 15, 2023 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required). See PAR-24-072
  • Dec 6, 2023 - Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional). See PAR-23-318
  • Sept 26, 2023 - Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional). See PAR-23-309
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). See NOFO PA-23-230.
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required). See NOFO PA-23-231.
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed). See NOFO PA-23-232.
  • July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required). See NOFO PA-23-233
  • May 10, 2023 – Dissemination and Implementation Research in Health (R21 Clinical Trial Optional). See PAR-22-109
  • May 10, 2023 – Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). See PAR-22-105. 
  • Feb 2, 2023 - NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional). See PAR-23-111. 
  • Jan 31, 2023 - Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional). See PAR-23-112
  • Jan 13, 2023 - Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed). See PAR-23-105
  • Jan 12, 2023 - Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed). See RFA-AG-24-001 
  • Jan 11, 2023 - Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional). See PAR-23-060
  • Jan 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional). See PAR-23-061
  • Jan 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional). See PAR-23-062
  • Jan 8, 2023 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial Optional). See PAR-24-064
  • Jan 6, 2023 – Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed). See PAR-23-095.
  • Dec 23, 2022 - Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) PAR-23-081
  • Dec 23, 2022 - Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional). See PAR-23-083
  • Dec 14, 2022 - National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional). See PAR-23-059
  • Dec 5, 2022 - NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional). See PAR-23-058
  • Sept 9, 2022 - NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional). See PAR-22-230
  • Sept 9, 2022 - NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional). See PAR-22-231
  • June 21, 2022 - Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional). See PAS-22-196
  • June 21, 2022 - Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional). See PAS-22-197
  • May 9, 2022 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional). See PAR-22-182
  • May 9, 2022 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional). See PAR-22-183 
  • Mar 31, 2022 - Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional). See PAR-22-145
  • Mar 10, 2022 - NIA Program Project Applications (P01 Clinical Trial Optional). See PAR-22-130 
  • Oct 12, 2021 - Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). See PAR-21-341  
  • Mar 3, 2021 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required). See PAR-21-131
  • Mar 2, 2021 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). See PAR-21-130 
  • Nov 24, 2020 - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required). See PAR-20-309
  • May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required). See PA-20-194
  • May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). See PA-20-195
  • May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required). See  PA-20-196
  • May 5, 2020 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required). See PA-20-184
  • May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See PA-20-185
  • May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Required). See PA-20-183

Issued by

Office of Behavioral and Social Sciences Research (OBSSR)

Office of AIDS Research (OAR)

National Eye Institute (NEI)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Center for Complementary and Integrative Health (NCCIH)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Sexual and Gender Minority Research Office (SGMRO)

Office of Research on Women's Health (ORWH)

Purpose

This Notice of Special Interest (NOSI) is being re-issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address adherence to recommended treatment and prevention regimens or maintenance of behaviors to promote positive health outcomes (collectively referred to as health behaviors). Applications may address health behavior initiation, execution, and/or persistence through mechanistic studies, efficacy trials, or implementation research. Descriptive studies and intervention research may address relevant determinants at one or more levels of ecologic influence, including the individual, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. The specific research interests of participating NIH Institutes, Centers, and Offices are detailed below.

Background

Increased adherence to recommended treatment and prevention regimens is an area of the behavioral and social sciences that promises substantial improvements in individual and public health, as well as savings in healthcare costs. Poor adherence to recommended healthcare regimens is common across many chronic health conditions and populations. This includes many recommended prevention, screening, treatment, monitoring, and health behavior regimens.

Current concepts of adherence are multidimensional. Adherence to a recommended healthcare regimen (e.g., taking a medication, following a diet, making dietary changes) comprises three components: initiation (starting the regimen behaviors), execution (enacting the regimen behaviors with fidelity), and persistence (sustaining the behaviors over time). Each component of adherence may present unique challenges and determinants, and each may require distinct behavioral and social interventions that rely on various mechanisms of action.

A particular challenge has been the long-term maintenance of health behaviors, since many people have difficulty turning a newly initiated health behavior into a consistent practice. Behavioral maintenance involves consistently performing a newly established health behavior to specified criteria over time and across contexts. The behavior may be one of omission (e.g., not smoking) or commission (e.g., flossing teeth). Maintaining health behaviors is a dynamic process in which people may cycle in and out of the behavior before reaching a regular practice and/or steady state, and the criteria for maintenance may be situational depending on the health outcome. The dynamic nature of adherence and long-term behavioral maintenance underscores the importance of improved monitoring of health behaviors and associated determinants to prompt the timely delivery of support interventions when needed.

The determinants of adherence and long-term behavioral maintenance span a broad ecologic spectrum. These range from characteristics of the illness and the healthcare or behavior regimen to individual and interpersonal influences. They also include larger structural influences like healthcare coverage, economic inequality, and structural racism. These multilevel determinants invite a range of possible interventions that address individuals, families, caregivers, health care providers, health care system factors, and/or communities to facilitate adherence and behavioral maintenance. Developing effective interventions requires careful specification and assessment of their mechanisms of action.

Multilevel approaches to improve adherence to treatment and preventive regimens and to achieve long-term behavioral maintenance are particularly important for addressing inequities in health outcomes. Marginalized and minoritized communities may lack access to healthcare and resources that support adherence and behavioral maintenance. In addition, they may experience barriers related to prejudice, discrimination, and intersectional stigma in healthcare settings. Achieving greater health equity across NIH-defined health disparity populations may therefore require interventions that not only address marginalized and minoritized communities, but also improve healthcare delivery itself.

Research to address challenges and inequities in adherence and behavioral maintenance will continue to benefit from close attention to scientific rigor. Studies will be expected to clearly define their outcomes, i.e., specifying the desired behavior change (e.g., initiation or maintenance), complement self-reported measures with objective assessments of behavior, and address intervention mechanisms of action. Grounding research and intervention in behavioral and social science theory will help specify intervention targets and mechanisms of action. Intervention studies are encouraged to consider enrolling individuals with documented challenges in adherence or behavioral maintenance to avoid ceiling effects that may prohibit a determination of intervention efficacy. Implementation studies designed to advance the adoption and use of evidenced-based interventions are encouraged.

Research Objectives

The objective of this NOSI is to encourage research grant applications that address adherence to recommended treatment and prevention regimens and maintenance of behaviors to promote health outcomes. Applications may address health behavior initiation, execution, and/or maintenance through mechanistic studies, efficacy trials, or implementation research. Descriptive and intervention research may address relevant determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged.

Research projects that could be addressed in response to this NOSI include, but are not limited to, the following topics. Further priorities specific to participating Institutes, Centers, and Offices subsequently follow.

  • Research to advance novel tools or improve implementation of existing approaches to monitor adherence and long-term behavioral maintenance to facilitate delivery of timely interventions.
  • Research that identifies the mechanisms of action that support behavior change to improve adherence and maintenance.
  • Research to understand and address individual, social, and structural determinants of health contributing to inequities in adherence and associated health outcomes among NIH-designated health disparity populations, including racial and ethnic minority groups, sexual and gender minority (SGM) groups, people with disabilities, people with lower socioeconomic status (SES), and underserved rural communities. 
  • Research examining interventions designed to optimize adherence and maintenance of health behaviors through caregivers, peers, or social support networks.
  • Studies of adherence-promoting behavior maintenance strategies that are delivered through technology tools, such as mobile health apps, mobile medical devices, and electronic health records.
  • Research testing the efficacy of interventions delivered at the healthcare provider or system-level that may facilitate patient adherence and maintenance of health behaviors.
  • Multilevel and multicomponent interventions (e.g., at the individual, healthcare provider, and community level) that improve adherence and behavioral maintenance.

IC Specific Application and Submission Information:

NIH ICs have separately advanced notices of funding opportunities (NOFOs) relevant to this NOSI. These NOFOs might be specific to each IC mission area. Applicants must select the IC and associated NOFO to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that NOFO.

National Center for Complementary and Integrative Health (NCCIH)

NCCIH is interested in research on the use of complementary and integrative health approaches to enhance adherence to treatment or prevention regimens and maintenance of behaviors to promote or restore health, prevent disease, as well as foster well-being, resilience, or symptom management. NCCIH is also interested in research to enhance adherence and maintenance of behaviors with complementary and integrative health approaches. Please see  https://www.nccih.nih.gov/about/strategic-plans-and-reports or a full description of NCCIH’s strategic priorities. For this NOSI, complementary and integrative health approaches of interest include those with physical and/or psychological therapeutic inputs, often called mind and body approaches (e.g., acupuncture, yoga, tai chi, qi gong, meditation, hypnosis, music-based interventions, art therapy, spinal and/or joint manipulation, or massage therapy). Also of interest are multi-component interventions such as a combination of two or more complementary health approaches or integrated approaches to care in which a complementary health approach is used in combination with standard care (e.g., mindfulness or yoga to improve adherence to conventional therapeutics). NCCIH will not support applications through this NOSI with a primary outcome of assessing the efficacy or effectiveness of the complementary and integrative approach on a clinical outcome (see https://nccih.nih.gov/grants/funding/clinicaltrials). Investigators are strongly encouraged to discuss their plans with NCCIH program staff prior to submitting their application.

National Cancer Institute (NCI)

NCI seeks research that will improve adherence to recommended cancer prevention and treatment regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability.  Research aimed at initiation, implementation and persistence of adherence-related behaviors is of interest. Multi-level studies and research aimed at high-risk, vulnerable, or underserved populations are encouraged. Priority topics include but are not limited to:

  • Improving adherence to lifestyle recommendations related to cancer incidence and outcomes, including diet, physical activity/sedentary behaviors, energy balance and obesity, UV protection, alcohol and tobacco use, and sleep.
  • Improving adherence to recommended cancer prevention regimens, cancer screening tests, treatment regimens, maintenance therapy, and follow-up care.
  • Improving adherence to oral cancer therapies, with an emphasis on immunotherapy and molecularly targeted therapies.
  • Understanding and addressing the effects of polypharmacy on symptoms and treatment adherence.
  • Developing system-level approaches to improve adherence, including research that addresses healthcare providers, healthcare team interactions, and aspects of care delivery.
  • Testing personalized approaches to improve adherence, including targeted and tailored adherence interventions and messages.
  • Innovative, theory-driven applications of mobile health, health IT, and social media platforms to monitor and improve adherence.
  • Developing novel interventions to improve adherence based on basic behavioral and social science findings (see ORBIT model for behavioral treatment development).
  • Identifying optimal approaches for disseminating and implementing evidence-based adherence interventions within systems of care and home, school, workplace and community settings.

National Eye Institute (NEI)

NEI seeks research on adherence to interventions/treatments in the context of vision health and impairment. Areas of interest include but are not limited to adherence to low vision rehabilitation training, myopia prevention/treatment, pediatric amblyopia therapies, and glaucoma treatment regimens. In addition, improving adherence to prevention efforts (e.g., eye care screening) or follow-up eye examinations and development of novel personalized approaches and/or technological tools (e.g., mobile health) to enhance adherence are welcome. In the context of this NOSI, clinical trial studies that are greater than minimal risk will not be supported. (Minimal risk is defined as the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.) Investigators are strongly encouraged to discuss their plans with NEI program staff prior to submitting their application.

National Heart, Lung, and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) is interested in adherence research and product development relevant to its Strategic Vision (https://www.nhlbi.nih.gov/about/strategic-vision), to promote and maintain heart, lung, blood, and sleep (HLBS) health. For this NOSI, NLHBI will support research across the translational spectrum, including observational and mechanistic studies as well as pilot or full-scale efficacy and effectiveness trials, for the development and evaluation of novel interventions to improve adherence to behavioral or pharmacologic regimens that promote and maintain heart, lung, blood, and sleep health.  NHLBI is also interested in supporting applications that include qualitative, quantitative, and mixed-methods research to understand and address the multi-level determinants of adherence across social and economic contextual factors. NHLBI recognizes the importance of research on interventions that focus on different target populations across the spectrum, from patients and family caregivers to healthcare providers and structural components of healthcare systems. Implementation research to identify and evaluate strategies to promote adoption of public health or clinical guidelines and evidence-based interventions is encouraged. NHLBI is interested in supporting adherence research across the stages of behavioral change, especially research focused on understanding and facilitating maintenance of adherence post-intervention and even beyond the project period.  Innovative uses of advances in behavioral science, mobile and connected health technology, healthcare informatics, and AI/ML technology, are encouraged. Regardless of the target population or the type of intervention, NHLBI encourages applications that integrate the patient perspective into intervention and implementation design, product development, and identification of patient-centered outcomes. NHLBI remains strongly committed to research that aims to mitigate adherence-related health disparities and improve health outcomes for high-risk communities, including NIH-designated populations that experience health disparities. Applications proposing clinical trials may require Milestone Accrual Plans and/or other performance milestones prior to award (see https://www.nhlbi.nih.gov/grants-and-training/policies-and-guidelines/accrual-of-human-subjects-milestones-policy). Investigators are strongly encouraged to discuss their plans with NHLBI program staff prior to submitting their application.

National Institute on Aging (NIA)

NIA seeks research on interventions to promote adherence to medical and behavioral regimens in mid- to late life aimed at preventing age-related diseases and cognitive decline and promoting healthy and adaptive aging. Aging itself remains the most significant risk factor for many chronic diseases and conditions, including Alzheimer’s disease and related forms of dementia (AD/ADRD), most types of cancer, many types of heart disease, osteoporosis and hip fracture, kidney failure, and diabetes. NIA applications under this NOFO are expected to articulate their research aims using the NIH Stage Model framework, identifying the Stage(s) of research proposed as defined by the NIH Stage Model. In addition, applications are encouraged to apply the experimental medicine approach, i.e. articulate or test a hypothesis to identify an intervention’s principles/mechanism(s) of action, as described by the NIH Science of Behavior Change Common Fund Program. Areas of interest include those that leverage current understanding of behavioral science, psychology of aging, or social and environmental contexts relevant to aging to promote adherence to exercise, healthful eating, prescribed medications, stress-reducing and/or positive affect inducing behaviors, and medical regimens. Of particular interest is the development of scalable principle-driven interventions that are highly relevant to the needs and capacities of individuals as they age; interventions that incorporate behavioral economic principles and/or technological innovations; interventions to prevent, treat, or improve care for individuals living with AD/ADRD; interventions with a geriatric focus on multiple chronic conditions that may involve polypharmacy; and interventions promoting adherence to screening, vaccination, and other preventive measures in older adults.

National Institute on Drug Abuse (NIDA)

NIDA is interested in research on the development of optimal behavioral strategies to promote adherence to medication-based and other substance use disorder (SUD) treatments. Applications are encouraged for studies that include, but are not limited to: improvements in drug abuse treatment adherence interventions for use in primary care; technologies to boost effects and increase efficiency of adherence interventions, and; interventions to promote adherence to HIV medications (including PrEP).

National Institute of Mental Health (NIMH)

NIMH has interest in adherence research in the context of mental health as well as HIV. Applicants are strongly encouraged to consult NIMH staff when developing plans for an application. Per NOT-MH-23-375, NIMH does not accept clinical trials testing for intervention efficacy or effectiveness through the NIH parent announcements. All NIMH applications that propose clinical trials to test adherence strategies are required to follow the NIMH’s experimental therapeutics approach to intervention development and testing (see Support for Clinical Trials at NIMH) and must be submitted through one of several NIMH-specific clinical trials NOFOs (below). Applicants are strongly encouraged to compliment any self-reported adherence measures with objective assessments of behavior. Adherence strategies can target patients, providers, clinics, and healthcare and/or other service systems. NIMH is particularly interested in research on adherence interventions that support the NIMH Strategic Plan for Research. Examples of NIMH-relevant research projects include but are not limited to: Adherence interventions designed to improve mental health or HIV health outcomes, along with examination of change mechanisms; applications that use existing patient-level data, such as electronic medical records and prescription refill or claim data, to support adherence; and stepped interventions or differentiated care approaches that use adaptive designs and decision rules based on participant responses to tailor and modulate intervention strategies

National Institute on Minority Health and Health Disparities (NIMHD)

NIMHD is interested in supporting research and interventions considering determinants from more than one domain or level of influence (see NIMHD Research Framework). NIMHD is particularly interested in research on adherence that supports the NIMHD.nih.gov/about/strategic-plan/. Intervention design should be based on theories from minority health and health disparities science. Research must focus on one or NIH-designated health disparity population (African American or Black, Hispanic or Latino, American Indian or Alaska Native, Asian, Middle Eastern or North African, Native Hawaiians or Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, sexual and gender minority populations, and people living with disabilities). Applications may include but are not limited to multi-disciplinary etiologic and intervention research projects in community settings that advance the understanding of the mechanisms, pathways, and processes related to adherence to health promotion behaviors (e.g., healthy eating, physical activity, safe infant sleep practices, etc.), preventive screening recommendations, medication or other medical treatment regimens, and/or chronic disease self-management strategies. Research may propose using available secondary data, health system data and/or collection of primary data. 

National Institute of Nursing Research (NINR)

The National Institute of Nursing Research (NINR) supports research aligned with our mission and strategic priorities, conducted by scientists from any discipline. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses practice, including homes, schools, workplaces, clinics, justice settings, and the community.

Office of AIDS Research (OAR)

OAR, as part of the NIH Office of the Director (OD), is interested in research to address HIV-related adherence across prevention, treatment, and care. This includes adherence as it applies to recommended treatment and prevention regimens and/or maintenance of behaviors to optimize health outcomes. This includes factors across the spectrum of HIV-related health behaviors. Because the NIH OAR does not award grants, applications must also be relevant to the objectives of at least one of the participating NIH Institutes and Centers (IC) listed in this announcement. Please contact the relevant IC program contacts listed for questions related to funding.

Office of Disease Prevention (ODP)

The ODP is the lead office at the NIH responsible for assessing, facilitating, and stimulating research in disease prevention. In partnership with the 27 NIH Institutes and Centers, the ODP strives to increase the scope, quality, dissemination, and impact of NIH-supported prevention research. The ODP is interested in providing co-funding support for research that has strong implications for disease and injury prevention and health equity and that includes innovative and appropriate research design, measurement, and analysis methods. For this NOSI, ODP is interested in in applications that promote adherence interventions that include, but are not limited to, health disparities/health equity research, development and implementation of multi-level preventive interventions that include populations that experience health disparities, and methods for the design and analysis of studies to evaluate multi-level preventive interventions. The ODP does not award grants; therefore, applications must be relevant to the objectives of at least one of the participating NIH ICs listed in this announcement. Please contact the relevant IC Scientific/Research Contact(s) listed for questions regarding IC research priorities and funding. The ODP only accepts co-funding requests from NIH ICs. For additional information about ODP, please refer to the ODP Strategic Plan.

Office of Research on Women's Health (ORWH)

ORWH is part of the Office of the Director, NIH, and works with the 27 NIH Institutes and Centers to advance rigorous research of relevance to the health of women. ORWH does not award grants but co-funds women’s health-related applications and research projects that have received an award from one of the participating NIH Institutes and Centers (ICs) listed in the announcement. Applications seeking ORWH co-funding should ensure that the proposed work is aligned with at least one goal and objective outlined in the Trans-NIH Strategic Plan for Women’s Health Research (https://www.nih.gov/women/strategicplan). For this NOSI, ORWH is particularly interested in projects that consider gender-related social and structural factors in the context of adherence, as well as the interaction of those factors with other social and structural determinants of health.

Sexual & Gender Minority Research Office (SGMRO)

The SGMRO develops and coordinates health- and research-related activities for sexual and gender minority (SGM; defined for NIH research in NOT-OD-19-139) populations independently and in conjunction with NIH institutes, centers, and offices (ICOs) and serves as a liaison to ensure that SGM communities and their needs are considered and represented in research activities across the agency. The SGMRO does not have grant-making authority. The office can only support grants deemed meritorious after review by one of the ICs participating in this announcement and after a co-funding request is initiated through the IC. Please reach out to the relevant Scientific/Research Contact(s) identified in this announcement with any questions about IC-specific research priorities and funding. More SGM- and SGMRO-specific information is available in the NIH Strategic Plan to Advance Research on the Health and Well-being of Sexual and Gender Minorities FY 2021-2025, SGM Research Portfolio Analyses, and on the Office’s Research Resources webpage. For this NOSI, SGMRO encourages research (particularly prevention, intervention, and clinical research, but other relevant types of research as well) that focuses on facilitating the initiation, improvement, and/or maintenance of adherence behaviors specifically among members of SGM communities and among SGM people who are members of other groups that experience health disparities and inequities. The office also encourages incorporation of relevant concepts (e.g., stigma, minority stress, social safety, intersectionality, structural -isms), approaches (e.g., trauma-informed research, community-led research, qualitative research), and frameworks (e.g., SGM Health Disparities Research FrameworkNIMHD Health Disparities Research Framework) as appropriate.

Application and Submission Information

This NOSI applies to due dates on or after 7/15/2024 and subsequent receipt dates through 7/14/2027.

Submit applications for this initiative using one of the following notices of funding opportunities (NOFOs) or any reissues of these announcements through the expiration date of this notice.

Applicants must select the IC and associated NOFO to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed to be considered responsive to that NOFO. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those NOFOs are acceptable and based on usual application-IC assignment practices.

Activity Code

NOFO

NOFO Title

Date of Publication

Participating IC(s)

R01

PA-20-183

Research Project Grant (Parent R01 Clinical Trial Required)

5/05/2020

NCCIH, NEI, NHLBI, NIDA, NIMHD

R01

PA-20-184

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

5/05/2020

NCI, NEI, NIDA

R01

PA-20-185

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

5/05/2020

NCCIH, NEI, NHLBI, NCI, NIMHD

R21

PA-20-194

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

5/07/2020

NCCIH, NEI, NIDA

R21

PA-20-195

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

5/07/2020

NCCIH, NEI, NIDA

R21

PA-20-196

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

5/07/2020

NEI, NIDA

R43/R44

PA-23-230

PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

7/12/2023

NCCIH, NCI, NEI, NHLBI, NIMHD

R43/R44

PA-23-231

PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)

7/12/2023

NCCIH, NCI, NEI, NHLBI, NIMHD

R41/R42

PA-23-232

PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

7/12/2023

NCCIH, NCI, NEI, NHLBI, NIMHD

R41/R42

PA-23-233

PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)

7/12/2023

NCCIH, NCI, NEI, NHLBI, NIMHD

R01

PAR-22-105

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

5/10/2022

NCCIH, NCI, NEI, NHBLI

R21

PAR-22-109

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

5/10/2022

NCCIH, NCI

R01

PAR-20-309

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

11/24/2020

NIA

R01

PAR-21-130

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

3/2/2021

NIMH

R34

PAR-21-131

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)

3/02/2021

NIMH

R21

PAR-21-341Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)10/12/2021

NCI

P01

PAR-22-130

NIA Program Project Applications (P01 Clinical Trial Optional)

3/10/2022

NIA

R01

PAR-22-145

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)

3/31/2022

NCI, NEI, NIMH

R34

PAR-22-182

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

5/09/2022

NIDA

R01

PAR-22-183

Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)

5/09/2022

NIDA

R43/R44

PAS-22-196

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

6/21/2022

NIA

R41/R42

PAS-22-197

Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

6/21/2022

NIA

R01

PAR-22-230

NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional)

9/09/2022

NINR

R21

PAR-22-231

NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional)

9/09/2022

NINR

R03

PAR-23-058

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)

12/05/2022

NCI

P01

PAR-23-059

National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)

12/14/2022

NCI

R34

PAR-23-060

Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional)

1/11/2023

NIMH

R21

PAR-23-061

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

1/11/2023

NIMH

R01

PAR-23-062

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

1/11/2023

NIMH

R01

PAR-23-081

Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)

12/23/2022

NIA

R61

PAR-23-083

Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)

12/23/2022

NIA

R01

PAR-23-095

Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)

1/06/2023

NIMH

R34

PAR-23-105

Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)

1/13/2023

NIMH

R21

PAR-23-111

NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

2/02/2023

NIMHD

R01

PAR-23-112

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)

1/31/2023

NCI, NEI, NIMH

UG3/UH3

PAR-24-064

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

12/08/2023

NIDA

R01

PAR-23-309

Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional)

9/26/2023

NCI, NEI, NIMH

R21/R33

PAR-23-318

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)

12/06/2023

NCI, NEI, NIMH

P30

RFA-AG-24-001

Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)

1/12/2023

NIA

R01

PAR-24-072

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)

12/15/2023

NCI

R01

PAR-24-083

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

12/21/2023

NCCIH

R34

PAR-24-084

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

1/20/2024

NCCIH

R01

PAR-24-086

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

12/21/2023

NCCIH

U24

PAR-24-087

Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)

12/21/2023

NCCIH

UG3/UH3

PAR-24-090

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

12/21/2023

NCCIH

R01

PAR-24-122

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

1/18/2024

NCI

All instructions in the SF424 (R&R) Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-OD-24-146” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative
  • Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff/Scientific Contacts listed on this NOSI well in advance of the application receipt date to better determine appropriateness and interest of the relevant Institute.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Inquiries

Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.

Scientific/Research Contact(s)

Jennifer N. Baumgartner, Ph.D.
National Center for Complementary and Integrative Health (NCCIH)
Phone: 301-402-4084 
Email: jennifer.baumgartner@nih.gov

Wendy Nelson, PhD, MPH
National Cancer Institute (NCI)
Telephone:240-276-6971
Email: nelsonw@mail.nih.gov

Cheri Wiggs, PhD
National Eye Institute (NEI)
Telephone: 301-451-2020
Email: cheri.wiggs@nih.gov

Laurie Friedman Donze, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-1408
Email: laurie.donze@nih.gov

Erin R. Harrell, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-480-9627
E-mail: erin.harrell@nih.gov

Evan Sullivan Herrmann
 NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)
Phone: 301-443-1428
E-mail: evan.herrmann@nih.gov

Michael J. Stirratt PhD 
National Institute of Mental Health (NIMH)
Telephone: 240-627-3875
Email: stirrattm@nih.gov

Shahrzad Mavandadi, PhD 
National Institute of Mental Health (NIMH)
Telephone: 301-827-1167
Email: shahrzad.mavandadi@nih.gov

Priscah Mujuru DrPH, MPH, RN
National Institute on Minority Health and Health Disparities (NIMHD)
Phone: 301-594-9765
E-mail: mujurup@mail.nih.gov

Karen Huss, PhD, RN, ANP-BC, FAAN, FAAAAI, FAHA
National Institute of Nursing Research (NINR)
Telephone: 301-594-5970
Email: hussk@mail.nih.gov

OBSSR, OAR, ODP, ORWH, and SGMRO do not directly award grants but may provide co-funding. Please contact one of the IC program contacts listed above for questions regarding funding interest.

Deborah Young-Hyman, PhD
Office of Behavioral and Social Sciences Research (OBSSR)
Phone: 301-451-0724
Email: deborah.young-hyman@nih.gov

Paul Gaist, PhD., MPH 
NIH Office of AIDS  Research (OAR)
Telephone: 301-435-7577
Email: gaistp@od31em1.od.nih.gov

JoyAnn Courtney, PhD
Office of Disease Prevention (ODP)
Phone: (301) 402-3911
E-mail: joyann.courtney@nih.gov

Balkissa Ouattara, MD, PhD, MPH
Office of Research on Women’s Health (ORWH)
Phone: 301-435-8405
Email: balkissa.ouattara@nih.gov

Christopher Barnhart, PhD
Sexual & Gender Minority Research Office (SGMRO)
Telephone: 301-594-8983
Email: christopher.barnhart@nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Debbie Chen
National Center for Complementary and Integrative Health (NCCIH)
Phone: 301-594-3788
Email: debbie.chen@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: crystal.wolfrey@mail.nih.gov

Karen Robinson Smith
 NATIONAL EYE INSTITUTE (NEI)
Phone: 301-435-8178
E-mail: kyr@nei.nih.gov

Annmarie Brasilemejac
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI)
Phone: (301) 827-8016
E-mail: brasilea@nhlbi.nih.gov

Ryan Blakeney
National Institute on Aging (NIA)
Phone: 301-451-9802
E-mail: blakeneyr@mail.nih.gov

Pamela G Fleming
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)
Phone: 301-480-1159
E-mail: pfleming@mail.nih.gov

Rita Sisco
National Institute of Mental Health (NIMH)
Telephone: 301-443-2805
Email: siscor@mail.nih.gov

Priscilla Grant, JD
NIMHD - NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES
Phone: 301-594-8412
E-mail: pg38h@nih.gov

Kelli Oster
National Institute of Nursing Research (NINR)
Telephone: 301-594-2177
Email: osterk@mail.nih.gov